Best GLP-1 Drug for Weight Loss in 2026: A Complete Ranking

Best GLP-1 Drug for Weight Loss in 2026: A Complete Ranking

The conversation around weight management has changed dramatically in recent years, largely thanks to a class of medications known as GLP-1 receptor agonists. Originally developed for type 2 diabetes, these drugs have shown remarkable effectiveness for chronic weight management. As we look toward 2026, the landscape is more advanced than ever, with several powerful options available.

This guide provides a clear, evidence-aware ranking of the best GLP-1 drugs for weight loss. Our goal is to help you understand the options so you can have a more informed conversation with your doctor. Consult your healthcare provider before starting any medication.

How We Ranked the GLP-1 Drugs

Choosing a medication is a personal decision, not a competition. However, a ranking can help clarify the differences between available treatments. We based our list on four key factors drawn from major clinical trials and real-world data:

• Efficacy: The average percentage of body weight lost by participants in landmark clinical studies. This is the most significant factor for many people.
• Safety and Tolerability: The frequency and severity of common side effects. Most GLP-1 drugs share a similar side effect profile (primarily gastrointestinal), but tolerability can vary.
• Administration: How the drug is taken. This includes the frequency (daily or weekly) and method (injection or oral pill), which can impact convenience and adherence.
• Established Use: How long the medication has been on the market and the breadth of research supporting its use for weight management.

The 2026 GLP-1 Ranking for Weight Loss

Based on the latest clinical data, here is our complete ranking of GLP-1 medications for weight management.

1. Tirzepatide (Zepbound)

Why it’s number one: Tirzepatide stands out because it is a dual-agonist, targeting both GIP and GLP-1 receptors. This dual action has produced the highest average weight loss among the medicines in this ranking. In the head-to-head SURMOUNT-5 trial in adults with obesity and no diabetes, tirzepatide led to an average 20.2% weight loss at 72 weeks, compared with 13.7% for semaglutide.

• Efficacy: In the SURMOUNT-1 clinical trial in adults with obesity or overweight without diabetes, participants taking the highest dose (15 mg) lost an average of 20.9% of their body weight over 72 weeks.
• Administration: It's a once-weekly injection, which many users find convenient.
• Considerations: Like other drugs in this class, the most common side effects are gastrointestinal, including nausea, diarrhea, and constipation. These are typically most pronounced when starting the medication or increasing the dose.

2. Semaglutide (Wegovy)

Why it’s number two: Before tirzepatide, semaglutide was the undisputed leader that redefined what was possible with anti-obesity medications. It remains an incredibly effective and widely studied option with a proven track record.

• Efficacy: The STEP 1 clinical trial in adults with obesity or overweight without diabetes showed that participants taking semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks. In March 2026 the FDA also approved a higher 7.2 mg dose (Wegovy HD) for chronic weight management, which produced more weight loss than the 2.4 mg dose in trials.
• Administration: Wegovy is also a convenient once-weekly injection.
• Considerations: Its side effect profile is very similar to tirzepatide, with gastrointestinal issues being the most common complaints. Its extensive history provides a wealth of data on long-term use.

3. Liraglutide (Saxenda)

Why it’s number three: Liraglutide was one of the first GLP-1 agonists approved specifically for weight management, paving the way for the newer medications. While its efficacy is lower than tirzepatide and semaglutide, it has the longest track record for this specific use.

• Efficacy: In the SCALE Obesity and Prediabetes trial, liraglutide 3 mg produced an average weight loss of around 8% of body weight over 56 weeks.
• Administration: Liraglutide requires a once-daily injection, which can be a drawback for those who prefer less frequent dosing.
• Considerations: As an older medication, it provides a long-term safety profile that some patients and providers find reassuring. The daily administration, however, makes it less convenient than the weekly options.

4. Oral Semaglutide (Wegovy pill, Rybelsus)

Why it’s number four: This medication’s key advantage is its form: it’s a pill, not an injection. For individuals with a strong aversion to needles, this is a significant benefit that makes treatment accessible.

• Efficacy: Rybelsus (up to 14 mg) is approved for managing type 2 diabetes, and its weight loss effect is more modest. In December 2025 the FDA approved the Wegovy pill (oral semaglutide 25 mg) for weight management in the US; in the OASIS 4 trial, people who took it as directed lost an average of 16.6% of body weight. Availability outside the US differs by country.
• Administration: It is a once-daily pill. However, it comes with strict rules: it must be taken with a small amount of water on an empty stomach at least 30 minutes before any other food, drink, or medication.
• Considerations: The convenience of a pill is balanced by the specific daily routine required for it to be effective. For those who can adhere to the regimen, it’s a valuable non-injectable alternative.

Newer Options to Ask About

As of October 2026, the FDA has also approved orforglipron (Foundayo, April 2026), a once-daily GLP-1 pill that can be taken without food or water restrictions. In its ATTAIN-1 trial, the highest dose led to about 12.4% average weight loss at 72 weeks. Other medicines, such as CagriSema, are still under regulatory review. Approval status and availability differ between the US, UK and India.

Safety Applies to Every Option

All of these medicines can cause serious side effects in rare cases, including pancreatitis (severe stomach pain that does not go away and may spread to the back), gallbladder problems, dehydration that can affect the kidneys, and serious allergic reactions; seek urgent medical help if these occur. US labels carry a boxed warning about thyroid C-cell tumours, so they are not used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. They are not used in pregnancy, and tirzepatide can make oral contraceptive pills less effective for a time after starting and after each dose increase.

Beyond the Ranking: Finding Your Best Fit

The "best" GLP-1 drug is the one that is right for you. This ranking is a starting point for a conversation, not a conclusion. Your healthcare provider will help you weigh several factors unique to your situation:

• Your Health Profile: Your overall health, medical history, and any co-existing conditions are the most important considerations.
• Your Goals: Your personal weight management goals will influence which level of efficacy is most appropriate.
• Lifestyle & Preferences: Your comfort with injections versus a daily pill and your ability to manage potential side effects will play a big role in your long-term success.

GLP-1s Are Tools, Not Cures

It is essential to view these medications as powerful tools to be used as part of a comprehensive weight management plan. Lasting success with GLP-1s is most often achieved when they are combined with meaningful lifestyle changes, including a balanced diet, regular physical activity, and behavioral support.

These drugs work by regulating appetite and improving metabolic function, giving you a significant advantage in making and sustaining these crucial lifestyle changes. But if the medication is stopped without these new habits in place, studies show that weight is often regained.

The journey to a healthy weight is personal and complex. The rise of effective medications like GLP-1 agonists has provided new hope and possibilities for millions. By understanding the options and working closely with a medical professional, you can make an informed choice that supports your long-term health. Consult your healthcare provider before starting any medication.

Sources

1. U.S. Food & Drug Administration (FDA). Zepbound (tirzepatide) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf
2. U.S. Food & Drug Administration (FDA). Wegovy (semaglutide) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, 387(3), 205-216. Retrieved from https://pubmed.ncbi.nlm.nih.gov/35658024/
4. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989-1002. Retrieved from https://pubmed.ncbi.nlm.nih.gov/33567185/
5. U.S. Food & Drug Administration (FDA). Saxenda (liraglutide) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl.pdf
6. American College of Cardiology. SURMOUNT-5: Greater Loss of Weight, Waist Circumference With Tirzepatide Than Semaglutide (2025). Retrieved from https://www.acc.org/latest-in-cardiology/journal-scans/2025/07/10/09/09/surmount-5
7. U.S. Food & Drug Administration (FDA). (2026). FDA approves higher-dose semaglutide (Wegovy HD). Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide
8. Novo Nordisk. (2025). Wegovy pill approved in the US as first oral GLP-1 for weight management. Retrieved from https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916472
9. Healio. (2026). FDA approves orforglipron, an oral GLP-1 for adults with obesity. Retrieved from https://www.healio.com/news/endocrinology/20260401/fda-approves-orforglipron-an-oral-glp1-for-adults-with-obesity